Age-specific differences in breast cancer treatment between screen-detected and non-screen-detected breast cancers in women aged 40–74 years at diagnosis in Sweden 2008–2017

Author:

Jonsson HåkanORCID,Andersson Anne,Mao Zheng,Nyström Lennarth

Abstract

Background and purpose: We have recently demonstrated that screen-detected invasive breast cancers had more favourable tumour characteristics than non-screen-detected. The objective of the study was to analyse differences in breast cancer treatment between screen-detected and non-screen-detected cases by age at diagnosis, with and without adjustment for tumour (T) and nodal (N) status, within a nationwide, population-based mammography screening programme utilising register data. Material and methods: Data spanning 2008–2017 were collected from the National Quality Register for Breast Cancer. Multivariable logistic regression analysis was used to estimate odds ratios and 95% confidence intervals for treatment disparities between screen-detected and non-screen-detected breast cancer. Results: Among 46,481 women diagnosed with invasive breast cancer aged 40–74 and invited for mammography screening, significant differences in treatment were observed. Screen-detected cases showed higher likelihoods of partial mastectomy compared to mastectomy, endocrine therapy, and radiotherapy, whereas chemotherapy and antibody therapy were less likely compared to non-screen-detected cases. However, when adjusting for surgery type, screen-detected cases showed lower likelihoods of radiotherapy. Age at diagnosis significantly influenced treatment odds ratios, with interactions observed for all treatments except radiotherapy adjusted for surgery. Differences increased with age, except for endocrine therapy. Radiotherapy adjusted for surgery type showed no age-related interaction. Adjusting for T and N did not alter these patterns. Interpretation: In general, screen-detected cases received less aggressive treatment, such as mastectomy, chemotherapy, and antibody therapy, compared to non-screen-detected cases. Disparities increased with age, except for endocrine therapy and radiotherapy adjusted for surgery. Differences persisted after adjusting for T and N, suggesting that these factors cannot solely explain the results.

Publisher

MJS Publishing, Medical Journals Sweden AB

Reference17 articles.

1. Statistics on new detected cancer cases 2021 (The National Board of Health and Welfare, in Swedish). 2022. [Cited date June 27, 2024] Available from: https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/statistik/2022-12-8308.pdf

2. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778–1786. https://doi.org/10.1016/S0140-6736(12)61611-0

3. Nyström L, Rutqvist L, Wall S, Lindgren A, Lindqvist M, Rydén S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet. 1993;341:973–978. https://doi.org/10.1016/0140-6736(93)91067-V

4. European guidelines on breast cancer screening and diagnosis (European Commission). 2023. [Cited date June 27, 2024] Available from: https://healthcare-quality.jrc.ec.europa.eu/ecibc/european-breast-cancer-guidelines

5. Fancellu A, Sanna V, Sedda ML, Delrio D, Cottu P, Spanu A, et al. Benefits of organized mammographic screening programs in women aged 50 to 69 years: A surgical perspective. Clin Breast Cancer. 2019;19:e637–e642. https://doi.org/10.1016/j.clbc.2019.04.013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3